CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anchor Therapeutics, Inc. today announced that it has entered into a collaborative agreement with Kyowa Hakko Kirin Co., Ltd. (KHK) to utilize Anchor’s proprietary pepducin technology to advance KHK’s internal G protein-coupled receptor (GPCR) drug discovery portfolio. This agreement takes advantage of Anchor’s expanded business strategy to offer its pepducin technology for use as in vitro and in vivo research tools, in addition to developing pepducin therapeutics.
